176 related articles for article (PubMed ID: 11773164)
1. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Cianfrocca M; Cooley TP; Lee JY; Rudek MA; Scadden DT; Ratner L; Pluda JM; Figg WD; Krown SE; Dezube BJ
J Clin Oncol; 2002 Jan; 20(1):153-9. PubMed ID: 11773164
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
Dezube BJ; Krown SE; Lee JY; Bauer KS; Aboulafia DM
J Clin Oncol; 2006 Mar; 24(9):1389-94. PubMed ID: 16549833
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Rudek MA; Figg WD; Dyer V; Dahut W; Turner ML; Steinberg SM; Liewehr DJ; Kohler DR; Pluda JM; Reed E
J Clin Oncol; 2001 Jan; 19(2):584-92. PubMed ID: 11208854
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
[TBL] [Abstract][Full Text] [Related]
5. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B
Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
8. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.
Toschi E; Barillari G; Sgadari C; Bacigalupo I; Cereseto A; Carlei D; Palladino C; Zietz C; Leone P; Stürzl M; Buttò S; Cafaro A; Monini P; Ensoli B
Mol Biol Cell; 2001 Oct; 12(10):2934-46. PubMed ID: 11598182
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.
Erlichman C; Adjei AA; Alberts SR; Sloan JA; Goldberg RM; Pitot HC; Rubin J; Atherton PJ; Klee GG; Humphrey R
Ann Oncol; 2001 Mar; 12(3):389-95. PubMed ID: 11332153
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
Brinker BT; Krown SE; Lee JY; Cesarman E; Chadburn A; Kaplan LD; Henry DH; Von Roenn JH
Cancer; 2008 Mar; 112(5):1083-8. PubMed ID: 18224669
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
[TBL] [Abstract][Full Text] [Related]
13. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.
Miles SA; Dezube BJ; Lee JY; Krown SE; Fletcher MA; Saville MW; Kaplan L; Groopman J; Scadden DT; Cooley T; Von Roenn J; Friedman-Kien A;
AIDS; 2002 Feb; 16(3):421-9. PubMed ID: 11834954
[TBL] [Abstract][Full Text] [Related]
15. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
Dezube BJ; Von Roenn JH; Holden-Wiltse J; Cheung TW; Remick SC; Cooley TP; Moore J; Sommadossi JP; Shriver SL; Suckow CW; Gill PS
J Clin Oncol; 1998 Apr; 16(4):1444-9. PubMed ID: 9552050
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
Uldrick TS; Wyvill KM; Kumar P; O'Mahony D; Bernstein W; Aleman K; Polizzotto MN; Steinberg SM; Pittaluga S; Marshall V; Whitby D; Little RF; Yarchoan R
J Clin Oncol; 2012 May; 30(13):1476-83. PubMed ID: 22430271
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Stebbing J; Wildfire A; Portsmouth S; Powles T; Thirlwell C; Hewitt P; Nelson M; Patterson S; Mandalia S; Gotch F; Gazzard BG; Bower M
Ann Oncol; 2003 Nov; 14(11):1660-6. PubMed ID: 14581275
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG
J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma.
Renwick N; Weverling GJ; Brouwer J; Bakker M; Schulz TF; Goudsmit J
AIDS Res Hum Retroviruses; 2002 Jul; 18(10):695-8. PubMed ID: 12167275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
